Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday
With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 30.3% to $4.95 during Monday’s pre-market session. The market value of their…
FDA Fast-Tracks Review Of Sarepta’s Groundbreaking Muscular Dystrophy Treatment With $1B Market In Sight
Sarepta's Elevidys efficacy supplement accepted for Duchenne muscular dystrophy treatment expansion, potential $1 billion yearly opportunity. FDA review goal: June 21, 2024.
Why DoorDash Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quarter.
Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.
12 Health Care Stocks Moving In Friday’s Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 25.2% to $2.73 during Friday’s pre-market session. The company’s market…
In-Depth Examination Of 13 Analyst Recommendations For Sarepta Therapeutics
In the preceding three months, 13 analysts have released ratings for Sarepta Therapeutics (NASDAQ:SRPT), presenting a wide array…
Gene Therapy Player REGENXBIO’s RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.